TSE:ASP

Acerus Pharmaceuticals Stock Forecast, Price & News

C$0.04
-0.01 (-18.18 %)
(As of 07/22/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.05
C$0.05
50-Day Range
C$0.04
C$0.05
52-Week Range
C$0.03
C$0.07
Volume21,000 shs
Average Volume143,474 shs
Market CapitalizationC$69.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ASP News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Acerus Pharmaceuticals logo

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions

What stocks does MarketBeat like better than Acerus Pharmaceuticals?

Wall Street analysts have given Acerus Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acerus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Acerus Pharmaceuticals
.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (TSE:ASP) issued its earnings results on Wednesday, May, 12th. The company reported ($0.01) earnings per share for the quarter. The business earned ($7.56) million during the quarter.
View Acerus Pharmaceuticals' earnings history
.

How has Acerus Pharmaceuticals' stock been impacted by COVID-19?

Acerus Pharmaceuticals' stock was trading at C$0.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ASP shares have increased by 0.0% and is now trading at C$0.05.
View which stocks have been most impacted by COVID-19
.

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the following people:
  • Mr. Edward Gudaitis, Pres, CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Gavin Damstra, Sr. VP of International Commercial
  • Dr. Christopher Sorli Ph.D., M.D., F.A.C.E., Chief Medical Officer
  • Mr. Chris Witty, Investor Relations
  • Mr. Kevin Thomas Hickey, Sr. VP of US Commercial
  • Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL

Who are some of Acerus Pharmaceuticals' key competitors?

What other stocks do shareholders of Acerus Pharmaceuticals own?

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASP stock can currently be purchased for approximately C$0.05.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals has a market capitalization of C$69.19 million and generates C$1.17 million in revenue each year.

How many employees does Acerus Pharmaceuticals have?

Acerus Pharmaceuticals employs 10 workers across the globe.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is www.aceruspharma.com.

How can I contact Acerus Pharmaceuticals?

The company can be reached via phone at 416-679-0771.


This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.